TY - JOUR T1 - Pretreatment Neutrophil Count and Platelet-lymphocyte Ratio as Predictors of Metastasis in Patients With Osteosarcoma JF - Anticancer Research JO - Anticancer Res SP - 1081 LP - 1089 DO - 10.21873/anticanres.15570 VL - 42 IS - 2 AU - YOSHIHIRO ARAKI AU - NORIO YAMAMOTO AU - KATSUHIRO HAYASHI AU - AKIHIKO TAKEUCHI AU - SHINJI MIWA AU - KENTARO IGARASHI AU - TAKASHI HIGUCHI AU - KENSAKU ABE AU - YUTA TANIGUCHI AU - HIROTAKA YONEZAWA AU - SEI MORINAGA AU - YOHEI ASANO AU - HIROYUKI TSUCHIYA Y1 - 2022/02/01 UR - http://ar.iiarjournals.org/content/42/2/1081.abstract N2 - Background/Aim: Systemic inflammation responses have been associated with cancer development, progression and metastasis. Little is known about the risk of metastasis based on inflammatory-based scores in patients with osteosarcoma. Patients and Methods: A total of 65 osteosarcoma patients without metastasis at presentation were enrolled in this retrospective study. All had been diagnosed histologically, and their laboratory data at the first visit were collected from medical records. The inflammation-based scores, tumor size, location, staging, pathological fracture, treatment methods, follow-up periods, and metastasis-free duration were evaluated. Results: A multivariate Cox regression analysis revealed that a high platelet-lymphocyte ratio (PLR) >116 [hazard ratio (HR)=3.8, 95% confidence interval =1.5-9.3; p<0.01], and neutrophil count (NC) ≤4,030/μl (HR=4.5, 95%CI=1.7-12.3; p<0.01), were independent risk factors significantly associated with metastasis of osteosarcoma patients. Conclusion: The combination of a high PLR >116 and NC ≤4,030/μl before treatment was a useful inflammatory-based prognostic indicator for metastasis in patients with osteosarcoma. ER -